KR102997319B1 - Wee1 키나아제 저해제로서 유용한 피리도피리미딘 유도체 - Google Patents

Wee1 키나아제 저해제로서 유용한 피리도피리미딘 유도체

Info

Publication number
KR102997319B1
KR102997319B1 KR1020247000364A KR20247000364A KR102997319B1 KR 102997319 B1 KR102997319 B1 KR 102997319B1 KR 1020247000364 A KR1020247000364 A KR 1020247000364A KR 20247000364 A KR20247000364 A KR 20247000364A KR 102997319 B1 KR102997319 B1 KR 102997319B1
Authority
KR
South Korea
Prior art keywords
cancer
tumor
lymphoma
cell
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247000364A
Other languages
English (en)
Korean (ko)
Other versions
KR20240044409A (ko
Inventor
오렌 길라드
조셉 바카
Original Assignee
아프레아 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아프레아 테라퓨틱스, 인크. filed Critical 아프레아 테라퓨틱스, 인크.
Publication of KR20240044409A publication Critical patent/KR20240044409A/ko
Application granted granted Critical
Publication of KR102997319B1 publication Critical patent/KR102997319B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247000364A 2021-06-04 2022-06-03 Wee1 키나아제 저해제로서 유용한 피리도피리미딘 유도체 Active KR102997319B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163196744P 2021-06-04 2021-06-04
US63/196,744 2021-06-04
PCT/US2022/032203 WO2022256680A1 (en) 2021-06-04 2022-06-03 Pyridopyrimidine derivatives useful as wee1 kinase inhibitors

Publications (2)

Publication Number Publication Date
KR20240044409A KR20240044409A (ko) 2024-04-04
KR102997319B1 true KR102997319B1 (ko) 2026-07-30

Family

ID=82321319

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247000364A Active KR102997319B1 (ko) 2021-06-04 2022-06-03 Wee1 키나아제 저해제로서 유용한 피리도피리미딘 유도체

Country Status (10)

Country Link
US (1) US20240254123A1 (enExample)
EP (1) EP4347592A1 (enExample)
JP (1) JP2024522304A (enExample)
KR (1) KR102997319B1 (enExample)
CN (1) CN117794932A (enExample)
AU (2) AU2022287033B2 (enExample)
CA (1) CA3225152A1 (enExample)
IL (1) IL309037A (enExample)
MX (1) MX2023014466A (enExample)
WO (1) WO2022256680A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240158972A (ko) 2022-03-07 2024-11-05 데비오팜 인터네셔날 에스 에이 소세포 폐암의 치료 방법
EP4777102A1 (en) 2023-09-14 2026-07-22 Debiopharm International SA Combination of a wee1 inhibitor and a pkmyt1 inhibitor
CN120189510A (zh) * 2023-12-21 2025-06-24 北京哲源科技有限责任公司 一种并环化合物的应用
TW202541810A (zh) 2023-12-22 2025-11-01 瑞士商德彪製藥國際公司 治療實體腫瘤之方法
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013126656A1 (en) * 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
WO2014167347A1 (en) 2013-04-11 2014-10-16 Almac Discovery Limited 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044406A1 (en) 2001-03-02 2003-03-06 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents
PE20080695A1 (es) * 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
GB201612095D0 (en) * 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
MX2020001235A (es) * 2017-08-01 2020-07-20 Recurium Ip Holdings Llc Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
GB201800378D0 (en) * 2018-01-10 2018-02-21 Almac Discovery Ltd Pharmaceutical compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013126656A1 (en) * 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
WO2014167347A1 (en) 2013-04-11 2014-10-16 Almac Discovery Limited 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorganic& medicinal chemistry letters, vol.29, no.12, pp.1481-1486

Also Published As

Publication number Publication date
AU2022287033B2 (en) 2025-04-17
AU2022287033A1 (en) 2024-01-18
WO2022256680A1 (en) 2022-12-08
MX2023014466A (es) 2024-05-02
EP4347592A1 (en) 2024-04-10
US20240254123A1 (en) 2024-08-01
AU2025204724A1 (en) 2025-07-10
CA3225152A1 (en) 2022-12-08
KR20240044409A (ko) 2024-04-04
CN117794932A (zh) 2024-03-29
JP2024522304A (ja) 2024-06-13
IL309037A (en) 2024-02-01

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)